Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% ...

At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with blast-phase chronic myeloid leukemia (CML) using data from a multi-institution ...

(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral blood ...

Leukemia is a blood cancer with abnormal white blood cell overproduction, affecting red blood cells and platelets, leading to anemia and infection risks. Diagnosis involves blood tests, bone marrow ...

Lenalidomide for Chronic Lymphocytic Leukemia Lenalinomide at a dose of 25 mg/day for relapsed chronic lymphocytic leukemia is associated with "unacceptable toxicity." Medscape Medical News, May 08, ...

The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...

Experts on chronic myeloid leukemia discuss how caregivers can collaborate with the health care team and support newly diagnosed patients. In your work with caregivers, how have you seen them ...